4.360USD0.00%Mkt Cap: 157.39M USDP/E: —Last update: 2026-06-01
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a on…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap157.39M USD
Enterprise Value70.66M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-35.17M USD
Revenue/Share—
Last Price4.360 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.16
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.91
EPS (TTM)-1.10
EPS (Forward)-1.04
52W Range
1.00057% of range6.910
52W High6.910 USD
52W Low1.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.29%
ROA-56.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.83M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-12.14%
Net Debt-85.29M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio15.73
Quick Ratio15.33
Book Value/Sh2.272 USD
Cash/Share2.368 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.000 USD
Target Range9.000 USD – 9.000 USD
# Analysts1
Ownership
Shares Out.36.02M
Float17.02M
Insiders18.87%
Institutions70.48%
Short Interest
Short Ratio2.9d
Short % Float2.78%
Short % Out.2.32%
Shares Short836.37K
Short (prev mo.)633.93K
Technical
SMA 504.066 (+7.2%)
SMA 2002.040 (+113.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)217.60K
Avg Vol (10d)267.01K
Technical Indicators
RSI (14)48.2
MACD0.1538
MACD Signal0.2158
MACD Hist.-0.0620
BB Upper5.012 USD
BB Middle4.625 USD
BB Lower4.239 USD
BB Width16.73%
ATR (14)0.4059 USD
Vol Ratio (20d)0.34x